1. Scrip
  2. >>Business

Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine

 
• By Sten Stovall

Sanofi Pasteur and AstraZeneca will collaborate over the UK pharma's monoclonal antibody MEDI8897 to develop and commercialize a pediatric vaccine against respiratory syncytial virus.

Child chest x-ray

Tapping each other's respective strengths, Sanofi's vaccines unit Sanofi Pasteur and AstraZeneca PLC 's biologics R&D arm MedImmune have joined forces to develop and commercialize a prophylactic vaccine against respiratory syncytial virus (RSV) in newborns and infants.

Under the deal announced Feb. 3, MedImmune LLC will do the clinical development while Sanofi Pasteur will lead the commercialization activities, leveraging the French group's strength and expertise in pediatric vaccines

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.